BioCryst Pharmaceuticals Highlights Efficacy of ORLADEYO
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has recently announced important new findings related to its product, ORLADEYO® (berotralstat), emphasizing its potential to significantly lower the frequency of attacks associated with hereditary angioedema (HAE) across various age groups. These findings, showcased during a recent workshop, reveal compelling data indicating that ORLADEYO is beneficial for patients ranging from young children to adults.
Research Overview and Key Findings
BioCryst presented three distinctive studies at an international workshop focused on C1-Inhibitor deficiency and angioedema. These studies made a compelling case for the efficacy of ORLADEYO as a prophylactic treatment for HAE, providing observable improvements in patients' quality of life and a decrease in symptoms.
Impact on Young Children
One critical component of the research was an interim analysis from the APeX-P study, which involved children aged 2 to 11. This open-label study examined the treatment effects of berotralstat, where children were given different dosages based on their weight. Prior to starting treatment, participants reported a significant number of missed school days due to HAE symptoms. However, the results showed that more than half of the children remained attack-free each month while on berotralstat. Notably, days with angioedema symptoms decreased from an average of 11% to just 4% within 12 weeks, with this improvement maintained for a remarkable 48 weeks.
Italian Expanded Access Program Results
Another study highlighted was the Italian Expanded Access Program (EAP), which provided berotralstat to patients at no cost before it became commercially available. Safety and symptom data were collected meticulously throughout the treatment. Results showed that patients experienced a marked increase in disease control metrics and an improvement in their overall quality of life. For example, Angioedema Control Test (AECT) scores improved considerably, indicating better management of their condition.
Ongoing Support for Adolescent Patients
The Berolife study also contributed valuable insights, particularly focusing on adolescents aged 12 to 17. This real-world study monitored the long-term tolerability and effectiveness of berotralstat, concluding that the treatment consistently reduced the frequency of attacks while maintaining a safety profile in line with other studies. Data showed a reduction in the average number of attacks, providing adolescents with a promising preventive option that fits into their daily lives.
About ORLADEYO and Its Use
ORLADEYO is unique, being the first oral therapy specifically designed to prevent HAE attacks in both adult and pediatric patients aged 12 years and older. Administering just one capsule per day helps mitigate the actions of plasma kallikrein, a key player in causing attacks. This predictable schedule simplifies adherence, which is crucial in managing chronic conditions like HAE.
Significant Safety Information
While ORLADEYO has shown effective prophylactic results, it’s important to note that the safety and efficacy of this medication for treating acute HAE attacks have not been established. Patients should adhere to the recommended dosage and be wary of potential drug interactions that may lower its effectiveness. Monitoring for side effects is essential, as with any medication.
BioCryst’s Commitment
BioCryst Pharmaceuticals remains dedicated to enhancing the lives of individuals affected by hereditary angioedema and other rare diseases through innovative drug development. Their rigorous research and commitment to clinical excellence continue to drive them forward in the biotech field. The company has successfully launched ORLADEYO and is continually advancing its drug pipeline to deliver effective therapies that provide relief and improve living conditions for patients facing such challenges.
Frequently Asked Questions
What is ORLADEYO?
ORLADEYO® (berotralstat) is an oral treatment designed to prevent attacks of hereditary angioedema (HAE) in patients aged 12 and older.
How does ORLADEYO work?
ORLADEYO functions by inhibiting plasma kallikrein, which plays a critical role in triggering HAE attacks.
What are the side effects of ORLADEYO?
The common side effects include abdominal pain, headache, and gastrointestinal issues such as vomiting or diarrhea.
Is ORLADEYO suitable for children?
Currently, ORLADEYO is indicated for children aged 12 years and older, with ongoing research on its safety and efficacy in younger patients.
How can patients report side effects?
Patients can report any suspected adverse reactions to BioCryst Pharmaceuticals or the FDA through their respective hotlines.
